-
12:09:11 AM

PRTC Stock News

05/09/23 2:00 AM
Nasdaq : PRTC
clinical triallow float
PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
PureTech Health plc, a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the U.S. Food and Drug Administration granted Fast Track designation to Vedanta’ s defined...
RHEA-AI
neutral
05/04/23 2:00 AM
Nasdaq : PRTC, AKLI
clinical triallow float
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
PureTech Health plc, a clinical-stage biotherapeutics company noted today that its Founded Entity, Akili, Inc., a leading digital medicine company, announced topline results of the STARS-ADHD-Adult clinical trial evaluating the efficacy and safety of EndeavorRxⓇ in adults with attention-deficit/hyperactivity disorder. STARS-ADHD-Adult was designed...
RHEA-AI
neutral
04/25/23 6:50 AM
Nasdaq : PRTC
low float
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
PureTech Health plc, a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead...
RHEA-AI
neutral
04/17/23 7:05 AM
Nasdaq : PRTC
clinical triallow float
PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
PureTech Health plc, a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced the publication of Phase 2 study results from its lead program, VE303, in the Journal of the American...
RHEA-AI
neutral
03/23/23 3:00 AM
Nasdaq : PRTC, RPRX
low float
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
Royalty Pharma has acquired an interest in PureTech’ s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds.. PureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense revenues due to PureTech.. As part of this transaction, PureTech has...
RHEA-AI
very positive
02/27/23 9:05 AM
Nasdaq : PRTC
low float
PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)
PureTech Health plc, a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health, a health technology company committed to bringing accessible health monitoring to everyone, in conjunction with the Massachusetts General Hospital Frontotemporal Disorders Unit, has been selected by the Massachusetts Artificial...
RHEA-AI
neutral
02/14/23 7:00 AM
Nasdaq : PRTC
low float
PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that it will advance LYT-300 for the potential treatment of anxiety disorders and postpartum depression. A placebo-controlled, Phase 2 a, proof-of-concept, social anxiety clinical trial in healthy...
RHEA-AI
positive